Zebra Capital Management’s Harvard Bioscience HBIO Stock Holding History

Zebra Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,233	Closed	-$53K	–	205
2020 Q4	$53K	Hold	1,233	–	–	0.07%	158
2020 Q3	$37K	Hold	1,233	–	–	0.06%	158
2020 Q2	$38K	Hold	1,233	–	–	0.05%	208
2020 Q1	$27K	Sell	1,233 -227	-16%	-$6.15K	0.04%	217
2019 Q4	$45K	Buy	+1,460	New	+$42K	0.04%	284
2019 Q2	–	Sell	-2,195	Closed	-$95K	–	484
2019 Q1	$95K	Buy	2,195 +285	+15%	+$10.3K	0.05%	419
2018 Q4	$61K	Buy	+1,910	New	+$75.3K	0.04%	372

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Zebra Capital Management's HBIO Position: Q1 2021 in Review

Zebra Capital Management sold out of Harvard Bioscience (HBIO) in Q1 2021, closing a stake of 1,233 shares — an estimated $53K sold.

Zebra Capital Management first reported a position in HBIO in Q4 2018 and held it in 7 quarters. The position peaked at $95K in Q1 2019. 87 funds tracked by Wall St. Rank hold HBIO as of Q1 2021.

Zebra Capital Management reported no remaining Harvard Bioscience position as of Q1 2021 after selling out during the quarter.
Zebra Capital Management sold 1,233 Harvard Bioscience shares in Q1 2021, an estimated $53K.
Zebra Capital Management first reported a position in Harvard Bioscience in Q4 2018 and held it in 7 quarters.
Zebra Capital Management's Harvard Bioscience position peaked at $95K in Q1 2019.
87 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2021.

Based on Zebra Capital Management's 13F filing for Q1 2021, filed 17 May 2021.